Nasdaq-listed shares of Tiziana Life Sciences (TLSA) rose 2% by Thursday afternoon after the company announced that it will ...

Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy ...

A nonbiologic oral IL-23 inhibitor is more effective and safer than an approved oral JAK inhibitor for moderate-to-severe ...

TZLS-501 is a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody (mAb) targeting both the membrane-bound and soluble forms of IL-6R. This dual mechanism of action not only blocks IL-6R ...

Icotrokinra is a first-in-class oral peptide drug that selectively inhibits the IL-23 receptor, disrupting IL-23 signaling ...

The use of interleukin-2 (IL-2)-directed therapies has been associated with systemic toxicities, regulatory T cell (Treg) activation and limited efficacy so far. Researchers from Regeneron ...

Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for ...

We last explored the relationship between IL-36 and generalized pustular psoriasis (GPP) and the use of spesolimab (SPEVIGO an IL-36 receptor antagonist) six months prior to its September 2022 FDA ...

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, ...

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.